Literature DB >> 11026995

Vigabatrin-associated visual field defects in children.

I M Russell-Eggitt1, D A Mackey, D S Taylor, C Timms, J W Walker.   

Abstract

PURPOSE: Vigabatrin (Sabril), a drug that blocks GABA transaminase, has been used in the treatment of epilepsy since 1989. There have been reports of irreversible constriction of the visual field in adult patients related to vigabatrin (VGB) therapy, resulting in reduced VGB usage in adults. Although used as a second or third line agent in adults, in children it is often considered as a first line treatment for several subgroups of seizures in spite of there being no way, in the majority of cases, to monitor visual fields. Some of these children have a pre-existing visual field defect as part of their primary disorder. We aimed to identify whether visual field loss due to VGB was occurring in our hospital.
METHODS: We have studied the results of ophthalmic examination in 14 children on VGB at Great Ormond Street Hospital who were able to perform Goldmann visual fields.
RESULTS: Ten of the 14 patients had constriction of their visual fields attributed to VGB. In addition there were 2 patients with suspicious visual field defects thought to be due to VGB. There was pre-existing visual pathway damage in 4 cases and in 2 of these optic disc pallor increased in association with constricted visual fields. However, the optic discs were normal in 7 patients in spite of visual field constriction. Visual acuity was generally normal in spite of gross visual field constriction.
CONCLUSIONS: We believe that VGB should be used with great caution where there is pre-existing visual pathway damage. In other cases the benefits should be considered in relation to the risks, which include irreversible visual field damage. At present visual fields can only be monitored by perimetry, which is often not possible in children with epilepsy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11026995     DOI: 10.1038/eye.2000.83

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  8 in total

1.  Vigabatrin and retinal changes.

Authors:  Hanne Jensen; Ole Sjö; Peter Uldall; Lennart Gram
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

2.  Vigabatrin associated retinal dysfunction in children with epilepsy.

Authors:  R Koul; A Chacko; A Ganesh; S Bulusu; K Al Riyami
Journal:  Arch Dis Child       Date:  2001-12       Impact factor: 3.791

Review 3.  The safety and tolerability of newer antiepileptic drugs in children and adolescents.

Authors:  Dean P Sarco; Blaise F D Bourgeois
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

4.  Visual field defects in pediatric patients on vigabatrin monotherapy.

Authors:  Francisco J Ascaso; María J Lopez; José A Mauri; José A Cristobal
Journal:  Doc Ophthalmol       Date:  2003-09       Impact factor: 2.379

5.  Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy.

Authors:  Sivan Durbin; Giuseppe Mirabella; J Raymond Buncic; Carol A Westall
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-11       Impact factor: 4.799

6.  Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children.

Authors:  J Raymond Buncic; Carol A Westall; Carole M Panton; J Robert Munn; Leslie D MacKeen; William J Logan
Journal:  Ophthalmology       Date:  2004-10       Impact factor: 12.079

7.  Changes in the electroretinogram resulting from discontinuation of vigabatrin in children.

Authors:  Carol A Westall; Rita Nobile; Sharon Morong; J Raymond Buncic; William J Logan; Carole M Panton
Journal:  Doc Ophthalmol       Date:  2003-11       Impact factor: 2.379

8.  Feasibility, Accuracy, and Repeatability of Suprathreshold Saccadic Vector Optokinetic Perimetry.

Authors:  Ian C Murray; Lorraine A Cameron; Alice D McTrusty; Antonios Perperidis; Harry M Brash; Brian W Fleck; Robert A Minns
Journal:  Transl Vis Sci Technol       Date:  2016-08-31       Impact factor: 3.283

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.